Search. Read. Cite.

Easy to search. Easy to read. Easy to cite with credible sources.

Articles by J Genest (4)

Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia: Results From the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and Meta-Analysis of Women From Primary Prevention Trials

S Mora, R. J Glynn, J Hsia, J. G MacFadyen, J Genest and P. M Ridker

Circulation 121 ( 9 ): 1069 - 1077 , 2010

Urotensin II Receptor Knockout Mice on an ApoE Knockout Background Fed a High-Fat Diet Exhibit an Enhanced Hyperlipidemic and Atherosclerotic Phenotype

N Bousette, P D'Orleans Juste, R. S Kiss, Z You, J Genest, W Al Ramli, S. T Qureshi, A Gramolini, D Behm, E. H Ohlstein, S. M Harrison, S. A Douglas and A. Giaid

Circulation Research 105 ( 7 ): 686 - 695 , 2009

Number Needed to Treat With Rosuvastatin to Prevent First Cardiovascular Events and Death Among Men and Women With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein: Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)

P. M Ridker, F. A.H Fonseca, J Genest, A. M Gotto, J. J.P Kastelein, W Koenig, P Libby, A. J Lorenzatti, B. G Nordestgaard, J Shepherd, J. T Willerson, R. J Glynn and for the JUPITER Study Group

Circulation: Cardiovascular Quality and Outcomes 2 ( 6 ): 616 - 623 , 2009

Rosuvastatin for Primary Prevention Among Individuals With Elevated High-Sensitivity C-Reactive Protein and 5% to 10% and 10% to 20% 10-Year Risk: Implications of the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial for "Intermediate Risk"

P. M Ridker, J. G MacFadyen, B. G Nordestgaard, W Koenig, J. J. P Kastelein, J Genest and R. J. Glynn

Circulation: Cardiovascular Quality and Outcomes 3 ( 5 ): 447 - 452 , 2010